Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

What is a "cancer vaccine" and is it the same as a COVID vaccine?

2.

Advances in "next generation" photoactive cancer therapy

3.

Nonmelanoma skin cancer has been linked to occupational exposure to solar UVR.

4.

Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis

5.

FDA Approves New Bladder Cancer First-Line Standard of Care.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot